Sentence examples for optimize the risk from inspiring English sources

Therefore, we group four adjacent channels and optimize the risk level.

There is no human activity or equipment that has zero rate of failure and safety technology has emerged to optimize the risk of failure.

However, more breast cancer associated risk variants should be incorporated to optimize the risk assessment.

If our investment bankers and fund managers can come up with creative products which optimize the risk-return balance, then clean energy could present an ideal investment opportunity for long-term investors looking for stable high yields, with the added bonus that such investment will help save the planet.

Furthermore, during treatment with bevacizumab, particular attention should be paid to monitoring and treating side effects in order to optimize the risk-benefit ratio.

Therefore, the most advanced approach to optimize the risk-benefit ratio of long-term low-dose GC treatment is the GC-chronotherapy, using a modified release (MR) prednisone (release during the night) and following the circadian rhythms.

As combined antiplatelet regimens become more widely used and newer agents offer more potent antiplatelet effects, it will become increasingly important to be able to optimize the risk-to-benefit ratio in individual patients.

By stratifying patients via PERSEVERE, one has the potential to optimize the risk-to-benefit ratio of a test agent having more than minimal risk, and consequently conduct more rational clinical trials.

The most important approach to optimize the risk-benefit ratio of glucocorticoids is to understand in more detail how the molecular mechanisms of genomic and nongenomic glucocorticoid actions - and their dose dependency - mediate the clinically wanted benefits but also the known adverse effects [ 125].

This implies that efforts to change behavior and strengthen the intention-behavior relationship of healthcare professionals to encourage physical activity in cardiovascular patients can optimize the cardiovascular risk profile of patients.

18– 58 With the regulatory approvals of ipilimumab and vemurafenib, critical questions have arisen for melanoma specialists regarding the use of these agents in order to optimize the benefit-risk profile for patients that harbor a BRAF mutation.